Kin-Cohort Analysis of LRRK2-G2019S Penetrance in Parkinson's Disease

    June 2011 in “ Movement Disorders
    Stefano Goldwurm, Sara Tùnesi, Silvana Tesei, Michela Zini, Francesca Sironi, Paola Primignani, Corrado Magnani, Gianni Pezzoli
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →